author-photo

Karine Miquel-Hebert

Erasmus University Medical Center

29

Papers

2593

Citations

Citation Trend

Filter By

Papers (22) Sort By

Journal Conference Others

Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent.

2015 Jacc-cardiovascular Interventions
Show All
- Source
- Cite
- Save
Citations (28)
The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trials.

2013 Eurointervention
Show All
- Source
- Cite
- Save
Citations (16)
Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial

2013 Heart
Show All
- Source
- Cite
- Save
Citations (75)
Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial.

2013 Eurointervention
Show All
- Source
- Cite
- Save
Citations (42)
Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial.

2012 Jacc-cardiovascular Interventions
Show All
- Source
- Cite
- Save
Citations (35)
VASCULAR RESPONSE OF THE SEGMENTS ADJACENT TO THE PROXIMAL AND DISTAL EDGES OF THE ABSORB EVEROLIMUS-ELUTING BIORESORBABLE VASCULAR SCAFFOLD: 6 MONTHS AND 1 YEAR FOLLOW-UP ASSESSMENT. A SERIAL INTRAVASCULAR ULTRASOUND RADIOFREQUENCY DATA ANALYSIS FROM THE FIRST IN MAN ABSORB COHORT B TRIAL

2012 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (1)
ABSORB II randomized controlled trial. A clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: Rationale and study design

2012 American Heart Journal
Show All
- Source
- Cite
- Save
Citations (104)
Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial.

2012 Eurointervention
Show All
- Source
- Cite
- Save
Citations (102)
FIRST SEQUENTIAL ASSESSMENT AT 6 MONTHS AND 2 YEARS OF THE 2ND GENERATION ABSORB EVEROLIMUS-ELUTING BIORESORBABLE SCAFFOLD: A MULTI-IMAGING MODALITY STUDY

2012 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (0)
Clinical ResearchInterventional CardiologyEvaluation of the Second Generation of a Bioresorbable Everolimus-Eluting Vascular Scaffold for the Treatment of De Novo Coronary Artery Stenosis: 12-Month Clinical and Imaging Outcomes

2011 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (0)